PSNL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

17.48M

+4.07%

-0.292

+26.81%

18.47M

-10.38%

-0.270

+50%

18.70M

+8.7%

-0.253

+9.78%

Estimates Revision

The market is revising Downward the revenue expectations for Personalis, Inc. (PSNL) for FY2025, with the revenue forecasts being adjusted by -4.44% over the past three months. During the same period, the stock price has changed by -0.25%.

Revenue Estimates for FY2025

Revise Downward

-4.44%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.15%

In Past 3 Month

Stock Price

Go Down

-0.25%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast PSNL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSNL is 10.60 USD with a low forecast of 9.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

9.00

Averages

10.60

High

12.00

Current: 0.000

Low

9.00

Averages

10.60

High

12.00

Morgan Stanley

Equal Weight

maintain

$5 -> $9

2025-11-11

Reason

Morgan Stanley

Price Target

$5 -> $9

2025-11-11

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Personalis to $9 from $5 and keeps an Equal Weight rating on the shares after the company announced Medicare coverage of its ultrasensitive NeXT Personal test for surveillance of cancer recurrence in breast cancer patients.

H.C. Wainwright

Buy

maintain

$10 -> $13

2025-11-11

Reason

H.C. Wainwright

Price Target

$10 -> $13

2025-11-11

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Personalis to $13 from $10 and keeps a Buy rating on the shares after the company received Medicare reimbursement for post-treatment monitoring for cancer recurrence in patients with stage II and III breast cancer. Encouragingly, the reimbursement is effective retroactively starting October 7, at a rate of $3,878 for the initial test and $1,158 for follow-up tests, the analyst tells investors in a research note.

Guggenheim

Subbu Nambi

Buy

maintain

$6 -> $12

2025-11-11

Reason

Guggenheim

Subbu Nambi

Price Target

$6 -> $12

2025-11-11

maintain

Buy

Reason

Guggenheim analyst Subbu Nambi raised the firm's price target on Personalis to $12 from $6 and keeps a Buy rating on the shares after the company announced Medicare coverage for NeXT Personal in breast cancer. This first covered indication keeps Personalis on track for their goal of two indications by year end, notes the analyst, who views this as "a major win for the story" that derisks the clinical revenue outlook for 2025.

H.C. Wainwright

Buy

maintain

$10

2025-11-06

Reason

H.C. Wainwright

Price Target

$10

2025-11-06

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Personalis to $10 from $8.50 and keeps a Buy rating on the shares following the Q3 report. Management continues to expect reimbursement approval for two indications before 2026 and states that the demand for NeXT Personal and clinical trial sample testing continues to grow, the analyst tells investors in a research note.

Lake Street

Thomas Flaten

Buy

maintain

$9 -> $11

2025-11-05

Reason

Lake Street

Thomas Flaten

Price Target

$9 -> $11

2025-11-05

maintain

Buy

Reason

Lake Street analyst Thomas Flaten raised the firm's price target on Personalis to $11 from $9 and keeps a Buy rating on the shares after the company reported Q3 revenue ahead of the guided range, the firm's estimate and consensus. While noting that Personalis lowered 2025 revenue guidance to reflect macro headwinds in the biopharma business, the firm argues that the key driver of future revenue growth and share price appreciation will be reimbursement.

H.C. Wainwright

Swayampakula Ramakanth

Buy

downgrade

2025-08-06

Reason

H.C. Wainwright

Swayampakula Ramakanth

Price Target

2025-08-06

downgrade

Buy

Reason

H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on Personalis to $8.50 from $9 and keeps a Buy rating on the shares post the Q2 report. The firm says the biopharma translational research delays lead to the lower guidance.

Valuation Metrics

The current forward P/E ratio for Personalis Inc (PSNL.O) is -7.46, compared to its 5-year average forward P/E of -4.86. For a more detailed relative valuation and DCF analysis to assess Personalis Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.86

Current PE

-7.46

Overvalued PE

0.49

Undervalued PE

-10.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.52

Current EV/EBITDA

-7.22

Overvalued EV/EBITDA

1.66

Undervalued EV/EBITDA

-8.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.38

Current PS

9.29

Overvalued PS

10.14

Undervalued PS

0.61

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 19169.64% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 19169.64% over the last month.

Sold

Bought

PSNL News & Events

Events Timeline

No data

News

4.5

01-08NASDAQ.COM

ARK Genomic Revolution ETF Falls 2.5%, Personalis Drops 9.8%

3.5

2025-12-31Newsfilter

Oncolytics Biotech Achieves 33% Response Rate with Pelareorep in KRAS-Mutant Colorectal Cancer

3.5

2025-12-31PRnewswire

Oncolytics Biotech Reports 33% Response Rate in KRAS-Mutant Colorectal Cancer with Pelareorep

People Also Watch

Frequently Asked Questions

What is Personalis Inc (PSNL) stock price today?

The current price of PSNL is 8.1 USD — it has decreased -3.28 % in the last trading day.

What is Personalis Inc (PSNL)'s business?

Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.

What is the price predicton of PSNL Stock?

What is Personalis Inc (PSNL)'s revenue for the last quarter?

Personalis Inc revenue for the last quarter amounts to 14.50M USD, decreased -43.62 % YoY.

What is Personalis Inc (PSNL)'s earnings per share (EPS) for the last quarter?

Personalis Inc. EPS for the last quarter amounts to -0.24 USD, decreased -62.50 % YoY.

What changes have occurred in the market's expectations for Personalis Inc (PSNL)'s fundamentals?

How many employees does Personalis Inc (PSNL). have?

Personalis Inc (PSNL) has 229 emplpoyees as of January 10 2026.

What is Personalis Inc (PSNL) market cap?

Today PSNL has the market capitalization of 719.32M USD.